Breast Cancer Diagnostic Market Research Based on Synthesis and Analysis on Techniques and Medical Applications Report 2019 – 2026
Breast cancer is a cancer that forms in cells of the breasts. It is characterized by a malignant tumor formed in the breast cells, which can spread to other parts of the body. It is typically observed in females and is diagnosed by doctors with the help of several tests to locate the site of initiation and the spread of the tumor to several parts of the body. Various symptoms are observed in breast cancer such as in a breast, change in the shape of breast, skin dimpling, and fluid leakage from the nipple, patches on the skin, etc. Breast cancer can be developed in normal individuals due to several risk factors that involve low physical exertion, alcohol consumption, obesity, menopause, family history, and delivering a child at an older age.
Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-sample/425
Breast cancer can be diagnosed at early stages by several screening tests namely yearly mammograms, CT scans, and MRI. Once the symptoms are visually detectable, an individual is advised to undergo a diagnostic test to confirm the suspects of breast cancer. These diagnostic tests are majorly carried out by biopsy in which a small amount of internal tissue is removed from the patient’s body and observed under the microscope to diagnose breast cancer. This diagnostic method can be carried out with the help of several diagnostic options like that of biopsy, clinical lab tests, ultrasound techniques that are available in the Breast cancer diagnostic market.
Market Dynamics- Drivers
Alarming rise in the incidence of breast cancer augmenting market growth
Growing incidence of breast cancer cases is expected to drive growth of the global breast cancer diagnostic market during the forecast period. According to the National Cancer Institute (NCI), 2015, in the U.S. around 232,340 females were encountered with breast cancer and out of which 39,620 cases were lethal. The data from NCI also suggests that 22.9% of female cancers in women account for breast cancer while, 18.2% of all the deaths caused due to cancer, contributes to breast cancer. The American Cancer Society (ACS) states that 1 out of 4 patients diagnosed with cancer are victims of breast cancer and is the most commonly observed cancer in females.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/425
Increase in the incidence of breast cancer worldwide is the prime reason for global breast cancer diagnostic market growth over the forecast period
Increasing incidence of breast cancer worldwide is expected to drive the market growth in the near future. According to the World Health Organizations (WHO), 89.7 per 100,000 people in Western Europe are affected by breast cancer per year. Moreover, growing awareness among people regarding regular check-ups for early detection of breast cancer, technological advancement in medical imaging technologies, funding provided by the government in research and development of breast cancer treatment and diagnostic techniques are responsible to fuel the global market of breast cancer diagnostics.
Moreover, the rise in the geriatric population offers high growth to the players of the global market. The WHO states that survival rates are around 80% in North America, Sweden, and Japan.
Market Dynamics- Restraints
High cost associated with installation of breast cancer diagnostic devices and imaging facilities coupled with side effects of radiation is expected to hamper growth of the global breast cancer diagnostic market over the forecast period.
Regional segmentation of the breast cancer diagnostic market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. In the case of regional segmentation, North America accounts for the highest in the global breast cancer diagnostic market followed by Europe. Moreover, emerging countries in Asia Pacific are potential players in boosting the global market due to factors like the growing population of patients, government investments in healthcare expenditure and revenues and awareness among people regarding the benefits of early detection of breast cancer.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/breast-cancer-diagnostic-market-425
Global Breast Cancer Diagnostic Market- Competitive landscape
Major players operating in the global breast cancer diagnostic market involves Hologic Inc., GE Healthcare, Phillips Healthcare, Fujifilm Holdings Corporation, Gamma Medica Inc., Toshiba Corporation, Aurora Imaging Technology Inc., and Dilion Technologies Inc. GE Healthcare holds a very strong position in the global breast cancer diagnostic industry due to its high investment costs in R&D that results in the introduction of advancement in the field.
In September 2019, Todos medical Ltd., entered into a non-binding Memorandum of Understanding (MOU) with Orot+ to expand their existing launch and distribution partnership for the commercial sale of Todos TM-B1 and TM-B2 breast cancer detection blood tests in Japan.
In July 2019, Exact Sciences Corp and Genomic Health Inc. entered into a definitive agreement in which these companies will create a leading global cancer diagnostics company. The combined company will offer two of the strongest and fastest-growing brands in cancer diagnostics, Cologuard and Oncotype DX.
In July 2019, Paragon Biosciences launched the seventh portfolio company, Qlarity Imaging LLC, which was founded to harness the value of artificial intelligence (AI) to improve medical outcomes.
In 2016, Myriad Genetics acquired Sividon Diagnostics, a leading breast cancer prognostics company. This Acquisition enhances its competitive position in the oncology diagnostics market.
In 2015, BioNTech AG launched MammaTyper, a CE-IVD marked molecular diagnostic test to stratify breast cancer patients by molecular subtyping of routine tumor tissue.
Global Breast Cancer Diagnostic Market- Taxonomy
The global breast cancer diagnostic market is segmented on the basis of diagnostic type, end-user, and geography.
By Diagnostic Type
- Ionizing breast imaging technologies
- Analog Mammography
- Full-field digital mammography (FFDM)
- 3D breast tomosynthesis
- Positron emission tomography/ Computed tomography (PET/CT)
- Molecular Breast imaging/ breast specific gamma imaging (MBI/BSMI)
- Positron emission mammography
- Non-ionizing imaging technologies:
- Breast MRI (Magnetic Resonance Imaging)
- Breast Ultrasound
- Optical Imaging
- Automated whole breast ultrasound (AWBU)
- Breast thermography
- Cancer research centers/ institutes
- Diagnostic Clinical laboratories
- Ambulatory Surgical centers
- North America
- Latin America
- Asia Pacific
- Middle East
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire